Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces new evidence to be presented by the Advanced Wound Management franchise and the recently acquired Osiris Therapeutics, Inc. at the Symposium on Advanced Wound Care (SAWC) and Wound Healing Society Spring (WHS) Conference to be held on May 7-11, 2019, in San Antonio, Texas. Osiris Therapeutics, Inc. is focused on developing and marketing regenerative medicine products for wound care, orthopaedics, and sports medicine, and the scientific content will complement that which will be presented at the conference by Smith & Nephew.
According to Alla Danilkovitch, PhD, Chief Scientific Officer at Osiris, “the clinical studies highlight the benefits of Osiris' placenta-based products, Grafix®, GrafixPL®, and Stravix®, for use in covering a variety of wound types.” The scientific studies describe the structure and properties of placental tissues preserved using Osiris’ Prestige LyotechnologySM, which retain all components of the native tissue including living cells but can be conveniently stored at ambient temperature. In addition, several symposia and live presentations will be available to attendees during the conference.
“With our combined portfolios, we will be presenting some truly exciting new evidence,” said Mike Zagger, SVP Advanced Wound Management US at Smith & Nephew. “In addition to the new evidence from Osiris, we are focusing on new developments in negative pressure wound therapy and biofilm management. We look forward to fruitful conversations with attending clinicians about how we can help reduce the human and economic consequences of wounds.”
Smith & Nephew will be exhibiting at booth 516 and Osiris Therapeutics, Inc. at booth 525. For a full overview of new evidence, please see here www.smith-nephew.com/sawc2019osiris
Enquiries
Media
Dave Snyder
+1 (978) 749-1440
Smith & Nephew
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has more than 16,000 employees and a presence in more than 100 countries. Annual sales in 2018 were $4.9 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.
To learn more about how we can help you get CLOSER TO ZERO™ delay in wound healing, please visit www.closertozero.com.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, researches, develops, manufactures, and commercializes regenerative medicine products intended to improve the health and lives of patients and lower overall healthcare costs. It has achieved commercial success with products in orthopaedics, sports medicine, and wound care, including the Grafix® product line, Stravix®, BIO4®, and Cartiform®. It continues to advance its research and development by focusing on innovation in regenerative medicine, including the development of bioengineered stem cell and tissue‑based products. More information can be found on the Company’s website, www.Osiris.com. (OSIR-G)
Osiris®, Grafix®, GrafixPL®, GrafixPL PRIME®, Stravix®, Cartiform®, and Prestige LyotechnologySM are the trademarks of Osiris Therapeutics, Inc.
BIO4® is a trademark of Howmedica Osteonics Corp., a subsidiary of Stryker Corporation.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.